[1] [1] KHALIL S, AL-RAHAWAN M G, AL-RAHAWAN M M. Periosteal mesenchymal chondrosarcoma of the tibia［J］. Skeletal Radiology, 2018, 47(5): 605.

[2] [2] TSUDA Y, OGURA K, HAKOZAKI M, et al. Mesenchymal chondrosarcoma: a Japanese Musculoskeletal Oncology Group (JMOG)study on 57 patients［J］. Journal of Surgical Oncology, 2017,115(6): 760-767.

[3] [3] GAO C P, LIU J H, HOU F, et al. Low-grade chondrosarcoma ofthe cricoid cartilage: a case report and review of the literature［J］.Skeletal Radiology, 2017, 46(11): 1597-1601.

[4] [4] NAZERI E, GOURAN SAVADKOOHI M, MAJIDZADEH-A K,et al. Chondrosarcoma: an overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutictargets［J］. Critical Reviews in Oncology Hematology, 2018, 131:102-109.

[5] [5] ZHANG H P, LI G Q, GUO W Z, et al. Oridonin synergisticallyenhances JQ1-triggered apoptosis in hepatocellular cancer cellsthrough mitochondrial pathway［J］. Oncotarget, 2017, 8(63):106833-106843.

[6] [6] LIERMANN J, NAUMANN P, FORTUNATO F, et al. Phytotherapeutics oridonin and ponicidin show additive effects combinedwith irradiation in pancreatic cancer in vitro［J］. Radiology andOncology, 2017, 51(4): 407-414.

[7] [7] LI C, WANG Q, SHEN S, et al. Oridonin inhibits VEGF-Aassociated angiogenesis and epithelial-mesenchymal transition ofbreast cancer in vitro and in vivo［J］. Oncology Letters, 2018,16(2): 2289-2298.

[8] [8] LI S, SHI D, ZHANG L, et al. Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulatingBcl-2［J］. Experimental and Therapeutic Medicine, 2018, 16(6):4859-4864.

[9] [9] SHI M, LU X J, ZHANG J, et al. Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosisin gastric cancer cells through p53-and caspase-3-mediated mechanisms［J］. Oncotarget, 2016, 7(16): 22623-22631.

[10] [10] BU H Q, SHEN F, CUI J. The inhibitory effect of oridonin oncolon cancer was mediated by deactivation of TGF-β1/SmadsPAI-1 signaling pathway in vitro and vivo［J］. Onco Targets andTherapy, 2019, 12: 7467-7476.

[11] [11] QI Qi, ZHANG Pei, LI Qixiang, et al. Effect of oridonin onapoptosis and intracellular reactive oxygen species level in triplenegative breast cancer MDA-MB-231 cells［J］. China Journal ofChinese Materia Medica, 2017, 42(12): 2361-2365.

[12] [12] LI Zhiming, LONG Feng, HUANG Yong, et al. Oridonin inhibitsthe proliferation, migration, and invasion of MDA-MB-231 breastcancer cells via CDC42/MAP3K10 signaling pathway［J］. Pharmacology and Clinics of Chinese Materia Medica, 2021, 37(6):37-42.

[13] [13] LIU Y, LIU J H, CHAI K, et al. Inhibition of c-Met promotedapoptosis, autophagy and loss of the mitochondrial transmembranepotential in oridonin-induced A549 lung cancer cells［J］. Journalof Pharmacy and Pharmacology, 2013, 65(11): 1622-1642.

[14] [14] JIN S, SHEN J N, WANG J, et al. Oridonin induced apoptosisthrough Akt and MAPKs signaling pathways in human osteosarcoma cells［J］. Cancer Biology & Therapy, 2007, 6(2): 261-268.

[15] [15] LU Y, SUN Y, ZHU J, et al. Oridonin exerts anticancer effect onosteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway［J］. Cell Death & Disease, 2018, 9(1): 15.

[16] [16] LIU Y, LIU Y Z, ZHANG R X, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-cateninsignaling［J］. International Journal of Oncology, 2014, 45(2):795-803.

[17] [17] WEI Xing, WANG Chunjiang, CAO Bo, et al. Exploration on theinduction of apop tosis on human osteosarcoma cells by podophyllotoxin derivate SQW-76 and its mechanism［J］. Journal ofBaotou Medical College, 2016, 32(7): 1-5.

[18] [18] PAN Qilu, MA Libing. Research progress based on the role ofepithelial-mesenchymal transition in the pathogenesis and invasionof malignant tumors［J］. The Journal of Practical Medicine, 2020,36(17): 2443-2447.

[19] [19] MITRA A, MISHRA L, LI S. EMT, CTCs and CSCs in tumor relapse and drug-resistance［J］. Oncotarget, 2015, 6(13):10697-10711.

[20] [20] CHEN Wei, YU Yue, SUN Yanxia, et al. Id1 and Id3 synergistically influence invasion and migration of colon cancer SW620cells by inducing EMT［J］. Chinese Journal of Cancer Biotherapy,2018, 25(10): 987-993.

[21] [21] LI G, YANG Y, XU S, et al. mir-21-5p inhibits the progression ofhuman chondrosarcoma by regulating CCR7/STAT3/NF-κB pathway［J］. Connective Tissue Research, 2021, 62(3): 313-324.

[22] [22] LIU Q Q, CHEN K, YE Q, et al. Oridonin inhibits pancreaticcancer cell migration and epithelial-mesenchymal transition bysuppressing Wnt/β-catenin signaling pathway［J］. Cancer CellInternational, 2016, 16: 57.

[23] [23] LI Zhiming, HUANG Yong, LONG Feng, et al. Inhibitory effectsof oridonin on proliferation, migration and invasion of humanbreast cancer cells by down regulating lncRNA AFAP1-AS1 expression［J］. Chinese Traditional Patent Medicine, 2022, 44(8):2483-2490.